General Information

Government Type

State Agency

Entity

Department of Health and Human Services (DHHS)

Public Body

Pharmacy and Therapeutics Committee

Notice Information

Add Notice to Calendar

Notice Title

State Medicaid P&T Committee Meeting

Notice Tags

Medicaid, Pharmacies

Notice Type(s)

Meeting

Event Start Date & Time

February 20, 2025 07:00 AM

Event End Date & Time

February 20, 2025 08:45 AM

Event Deadline Date & Time

02/20/25 08:45 AM

Description/Agenda

Pharmacy & Therapeutics Committee Meeting Agenda Thursday, February 20, 2025 7:00 a.m. to 8:45 a.m. Google Meet joining information Video call link: meet.google.com/zue-rrqz-rpb Or dial: (US) +1 904-900-0180 PIN: 172 873 306 # Persons who wish to address the P&T Committee may contact Ngan Huynh at (nganhuynh@utah.gov) before the meeting or sign up to provide comments at the meeting. Public comments will be limited to 3 minutes per speaker or organization due to time constraints. 1) Call to order - Cole Sloan, PharmD, Chair a) Announce Quorum 2) Welcome and Introductions - Cole Sloan, PharmD, Chair a) Review and Approval of Minutes b) Housekeeping i) Nomination of new P&T Chair ii) UT Medicaid Staff Update iii) DUR Board Chair Update 3) DUR Board Update - Luis Moreno, PharmD 4) Review a) EGFR Inhibitors For Approved Oncologic Disorders - Monet Luloh, PharmD i) afatinib (GILOTRIF®), amivantamab (RYBREVANT®), cetuximab (ERBITUX®), dacomitinib (VIZIMPRO®), erlotinib (TARCEVA®), gefitinib (IRESSA®), lapatinib (TYKERB®), lazertinib (LAZCLUZE®), necitumumab (PORTRAZZA®), neratinib (NERLYNX®), osimertinib (TAGRISSO®), panitumumab (VECTIBIX®), vandetanib (CAPRELSA®) b) Committee Discussion/Questions c) Committee Action 5) Next Meeting Thursday, May 15, 2025 - Agents with anti-ALK, RET, MET 6) Adjourned - Cole Sloan, PharmD, Chair Tentative Upcoming Pharmacy & Therapeutics Committee Schedule **Please note: all topics are tentative and subject to change** Month 15 May 2025 Topic Agents with anti-ALK, RET, and/or MET activity Agents alectinib, brigatinib, capmatinib ceritinib, crizotinib, lorlatinib, pralsetinib, selpercatinib, tepotinib The foundation documents used for most reviews are prepared by the University of Utah, College of Pharmacy, and are posted on the P&T Committee website after the meeting. Manufacturers wishing to submit any additional materials they would like reviewed as part of the process to: Dr. Joanne LaFleur College of Pharmacy 30 South 2000 East SLC, UT 84112-5820 All materials must be clearly labeled so that they are submitted for consideration as part of the state of Utah Medicaid Preferred Drug List Program review process. Materials must be received at least 60 days before the scheduled review date. Materials most useful to support the evidence-based process include any new evidence (information from clinical trials or studies when possible), unpublished materials the company would like considered as part of the process, or any other materials not likely to be included in a literature search.

Notice of Special Accommodations (ADA)

In compliance with the Americans with Disabilities Act, individuals needing special accommodations (including auxiliary communicative aids and services) during this meeting should notify Ngan Huynh at 801-538-6149.

Notice of Electronic or Telephone Participation

Video call link: meet.google.com/zue-rrqz-rpb Or dial: (US) +1 904-900-0180 PIN: 172 873 306 #

Meeting Information

Meeting Location

Video/Teleconferencing
Video/Teleconferencing, UT 84116
Show in Apple Maps Show in Google Maps

Contact Name

Ngan Huynh

Contact Email

nganhuynh@utah.gov

Contact Phone

801-538-6155

Notice Posting Details

Notice Posted On

February 06, 2025 11:54 AM

Notice Last Edited On

February 06, 2025 11:54 AM

Deadline Date

February 20, 2025 08:45 AM

Subscribe by Email

Subscription options will send you alerts regarding future notices posted by this Body.